Trial site
Retina Specialty Institute
Pensacola, Florida 32503, United StatesNot linked to an institution yet
- 12running trials
- 9closed trials
The trials here
What the 21 trials at this site are about, from their registry records.
- Phase
- Phase 310 trials
- Phase 26 trials
- Phase 11 trial
- Phase 1/21 trial
- Phase 2/31 trial
- Phase 41 trial
- Status
- Active, not recruiting9 trials
- Completed9 trials
- Recruiting3 trials
- Lead sponsor
- Hoffmann-La Roche5 trials
- 4D Molecular Therapeutics2 trials
- EyePoint Pharmaceuticals, Inc.2 trials
- Janssen Research & Development, LLC2 trials
- Alcon Research1 trial
- and 9 more
Running trials
Active, not recruiting
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07449923· Phase 3· EyePoint Pharmaceuticals, Inc.· Source
Recruiting
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
NCT06659445· Phase 2· ONL Therapeutics· Source
Contact: Study Coordinator
Recruiting
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT07064759· Phase 3· 4D Molecular Therapeutics· Source
Contact: 4DMT Patient Advocacy
Active, not recruiting
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT06864988· Phase 3· 4D Molecular Therapeutics· Source
Active, not recruiting
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
NCT06495918· Phase 3· Ocular Therapeutix, Inc.· Source
Active, not recruiting
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
NCT06668064· Phase 3· EyePoint Pharmaceuticals, Inc.· Source
Recruiting
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT06635148· Phase 2/3· Janssen Research & Development, LLC· Source
Active, not recruiting
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT05769153· Phase 1/2· Alcon Research· Source
Active, not recruiting
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
NCT05476926· Hoffmann-La Roche· Source
Active, not recruiting
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
NCT04853251· Phase 4· Genentech, Inc.· Source
Active, not recruiting
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
NCT04108156· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
NCT03178149· Phase 1· Astellas Institute for Regenerative Medicine· Source
Contact: Astellas Institute for Regenerative Medicine
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error